ALAntonella Lombardo

Antonella Lombardo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Antonella Lombardo has a total of 166 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Rationale and Design of the CARdio-Tox Study: A Prospective Evaluation of Cardiovascular Toxicity in Patients Receiving Chimeric Antigen Receptor-T (CAR-T) Cell Therapy

    by Massimiliano Camilli, Michela Ortenzi, Ludovica Leo, Marcello Viscovo, Eugenio Galli, Priscilla Lamendola, Ludovica Amore, Stefan Hohaus, Simona Sica, Filippo Crea, et al.

    Chimeric Antigen Receptor (CAR)-T cell therapy has emerged as an innovative treatment of haematologic malignancies; however, its use is frequently complicated by Cytokine Release Syndrome (CRS), an increasingly recognized driver of cancer therapy-related cardiovascular toxicity (CTR-CVT) able to provoke a wide spectrum of manifestations, from paucysimptomatic and reversible effects to potentially fatal cardiovascular damage. The 2022 European Society of Cardiology (ESC) guidelines on cardio-oncology highlighted the need for systematic cardiovascular assessment in patients receiving CAR-T therapy, yet specific monitoring protocols are lacking at this point in time. The CARdio-Tox study was conceived to address this surveillance gap, testing the hypothesis that acute systemic inflammation, particularly mediated by high levels of interleukin (IL)-1 and IL-6 pathways, might represent the key determinant of early myocardial dysfunction. The primary endpoint of this protocol is to assess the incidence of acute CTR-cardiac dysfunction (CTRCD) occurring within 7 and 30 days after CAR-T cell infusion. Key secondary endpoints include the assessment of the relationship between CTRCD occurrence and CRS diagnosis and grade, as well as the association of inflammatory biomarkers increase with cardiac imaging and/or serum biomarker abnormalities. Data collection will continue over 30 days to assess middle and long-term cardiovascular toxicity. Despite its single-center design, the CARdio-Tox results might provide clinically relevant insights into early cardiovascular effects of CAR-T cell administration, identify key risk factors for CTR-CVT and support more tailored, pathophysiology-driven monitoring strategies in this rapidly evolving field.

  • Open Access

    Agreement among four methods for estimating predicted prosthesis–patient mismatch and their relation to the residual echocardiographic gradient and survival in transfemoral TAVI

    by Roberto Pier Nicola Bellavia, Francesco Bianchini, Enrico Romagnoli, Cristina Aurigemma, Mattia Lunardi, Fabio Casamassima, Giuseppe Saglioccolo, Francesco Auletta, Federico Di Pasquale, Alessandro Roscioli, et al.

    Background. Before transcatheter aortic valve implantation (TAVI), predicted prosthesis–patient mismatch (PPM) is graded from a reference effective orifice area (EOA) taken from interchangeably-used sources that were never compared.Methods. In 1,419 consecutive transfemoral native-valve TAVI patients, predicted EOA was derived four ways: Transcatheter Valve Therapy (TVT) registry values; manufacturer/bench values (IFU/Bench); a CT-derived EOA from the CT-indicated size; and the CT annular area directly (PPMp2), graded by VARC-3. With no method as reference, the four were compared against each other, the residual gradient and mortality.Results. No patient had severe PPM; moderate PPM ranged 0.6–11.7%. The methods were not equivalent (Cochran Q = 78.9, p < 0.001), five of six pairs differing. For a gradient ≥20 mmHg, TVT registry and CT-derived-EOA were indistinguishable (ΔAUC 0.019, p = 0.103), whereas TVT registry outperformed IFU/Bench (0.057, p = 0.010) and PPMp2 (0.106, p = 0.005). Over a median 36.7 months, 363/1,177 died; no method predicted mortality (hazard ratios 0.99–1.13, all p > 0.45; C-indices 0.51–0.53).Conclusions. The sources differ and rank against the residual gradient, yet none is prognostic. Predicted PPM is a measurement problem, not a risk marker: the EOA source and VARC-3 threshold should always be stated.

  • Open Access

    Prevalence and Prognostic Value of Right Ventricular–Pulmonary Artery Uncoupling in Adults with Right-Sided Congenital Heart Disease

    by Giulia Iannaccone, Alessandro Olimpieri, Maria C. Meucci, Rosa Lillo, Maria Grandinetti, Alessio Cianci, Claudio Di Brango, Angelica B. Delogu, Massimo Massetti, Gaetano A. Lanza, et al.

    Background: Right-sided congenital heart diseases (R-CHDs) are frequently associated with right ventricular (RV) dysfunction and heterogeneous clinical trajectories, underscoring the need for individualized risk assessment. RV–pulmonary artery (RV–PA) coupling has emerged as an important prognostic marker in several cardiovascular conditions. However, its role in adults with R-CHD has not been well established. Methods: We retrospectively reviewed consecutive adults with R-CHD evaluated at our outpatient clinic between October 2013 and November 2023. RV–PA uncoupling was defined by echocardiography as a tricuspid annular plane systolic excursion (TAPSE) to pulmonary artery systolic pressure (PASP) ratio ≤0.55. The primary composite endpoint included all-cause mortality, major supraventricular and ventricular arrhythmias, unplanned cardiac hospitalizations, and need for (re)-interventions. Results: A total of 132 patients (mean age 41.6 ± 15.7 years; 51.5% male) were included. RV–PA uncoupling was identified in 48 patients (36.4%). Over a median follow-up of 40.3 months, the primary composite endpoint occurred in 71 patients (53.8%). Patients experiencing adverse outcomes were older and showed lower TAPSE, higher PASP, larger RV and right atrial dimensions, and a significantly higher prevalence of RV–PA uncoupling (p < 0.001). Multivariable Cox regression analysis demonstrated that RV–PA uncoupling was a strong independent predictor of adverse outcomes (HR 4.478, p < 0.001), outperforming its individual components. In addition, RV–PA uncoupling and RV mid-diameter independently predicted the need for surgical or interventional procedures during follow-up. Conclusions: RV–PA uncoupling provides robust and independent prognostic information in adults with R-CHD and represents a practical tool for personalized risk stratification, potentially guiding tailored surveillance strategies and timing of therapeutic interventions.

  • Open Access

    Rupture of Caseous Calcification of the Mitral Annulus: Pathophysiology, Diagnosis and Treatment

    by Aureliano Ruggio, Antonietta Belmusto, Gabriella Locorotondo, Eleonora Ruscio, Francesca Graziani, Antonella Lombardo, Gaetano Antonio Lanza, Francesco Burzotta

    Caseous calcification of the mitral annulus (CCMA) is a liquefactive necrosis of mitral annular calcification (MAC). CCMA is rare and usually asymptomatic, has a benign course, and, when incidentally found, can be misdiagnosed as a thrombus, abscess, cardiac tumor or vegetation. Although rarely, CCMA may complicate with rupture, which can lead to ventricular-atrial fistulization, pseudoaneurysm, severe mitral regurgitation (with possible heart failure and atrial fibrillation) and systemic embolism of caseous material (with cerebral ischemic events). A significant increase in CCMA dimensions and an infectious involvement of liquefactive necrosis make CCMA prone to rupture. To date, only case reports and some case series have been published on CCMA, without focusing on the pathophysiological mechanisms responsible for rupture, nor recommendations for prevention and management. However, despite general concerns about surgical treatment of CCMA because of high perioperative risks, most published cases actually underwent successful cardiac surgery. In the present review, we conducted a systematic review of the studies published in the medical literature up to March 2025, reporting cases of CCMA and its complications, as identified through the PubMed database. We analyzed clinical and biological risk factors for CCMA rupture and its diagnostic criteria, focusing on imaging features differentiating mitral annular calcification from uncomplicated CCMA and ruptured CCMA. To this regard, we focused on the key role of multimodality imaging in the achievement of the correct diagnosis. Finally, we propose a management strategy for CCMA, with the aim to fill a gap in this field in the current literature.


  • Open Access

    Endocarditis Team? Designing an Original and Tailored Clinical Pathway

    by Natalia Pavone, Maria Calabrese, Federico Cammertoni, Gessica Cutrone, Edoardo Maria D’aCierno, Piergiorgio Bruno, Maria Grandinetti, Giancarlo Scoppettuolo, Carlo Torti, Andrea Scapigliati, et al.

    Infective endocarditis (IE) is a complex and often misunderstood disease, carrying a substantial burden of morbidity and mortality. Over the past two decades, its incidence has risen steadily, accompanied by a growing predominance of highly virulent pathogens. Despite substantial advances in diagnostic tools, surgical techniques and perioperative management, IE continues to present major clinical challenges. In-hospital mortality remains extremely high, ranging from 15 to 30%, with a one-year mortality exceeding 40% in specific patient groups. In addition to its clinical impact, IE imposes a substantial economic burden, primarily due to prolonged hospitalization, extensive diagnostic work-ups, complex surgical interventions and long-term antibiotic therapy and follow-up. In such a complex scenario, delays in diagnosis and treatment are unfortunately common, often leading to fragmented and inefficient healthcare pathways, resulting in suboptimal patient management and compromised clinical outcomes. In response to these challenges, a dedicated Clinical Pathway (CP) for IE patients has been implemented to enhance interdisciplinary collaboration and ultimately improve patient outcomes.


  • Open Access

    Atrial Strain Analysis Predicts Atrial Arrhythmia Recurrence Following Cavotricuspid Isthmus Ablation of Typical Atrial Flutter

    by Giulia Iannaccone, Roberto Scacciavillani, Francesca Graziani, Filippo Tusa, Carlo Piccinni, Francesca Augusta Gabrielli, Maria Lucia Narducci, Francesco Perna, Massimiliano Camilli, Maria Chiara Meucci, et al.

    Background: This study aimed to evaluate the effectiveness of right and left atrial strain reservoir (RASr and LASr) in predicting the recurrence of atrial arrhythmias (AAs) following cavotricuspid isthmus ablation (CTIA) for typical atrial flutter (AFL). Methods: We retrospectively enrolled consecutive patients with AFL who had undergone CTIA. Transthoracic echocardiography was conducted within one month before the procedure, and atrial two-dimensional speckle tracking analysis was performed offline. Results: Sixty-two subjects were evaluated (mean age 64.8 ± 13.2 years, 29% females). At a median follow-up of 12.1 months, AA recurrence occurred in 21 subjects (33.8%). The study endpoint occurred mainly among females (p = 0.021) and patients with lower RASr and LASr values (both p < 0.001). In Cox regression analysis, RASr and LASr remained independent predictors of AA recurrence (p = 0.02 and p = 0.03, respectively). In ROC curve analysis, RASr and LASr showed a similar and satisfactory ability to predict AA recurrence with optimal cut-off values of 16.8% and 17.7%, respectively. In survival analysis, RASr > 16.8% and LASr > 17.7% were associated with significantly higher freedom from AAs during follow-up (log rank p = 0.001 and p = 0.002, respectively). Conclusions: The results of this study suggest that pre-CTIA atrial speckle tracking analysis may aid in identifying AFL patients at an increased risk of AA recurrence, allowing for more frequent follow-up visits and extended antiarrhythmic therapy.

  • Open Access

    1-Month Relapse of Undifferentiated Sarcoma in the Left Atrium

    by Isabella Fumarulo, Massimiliano Camilli, Irma Bisceglia, Massimo Massetti, Antonella Lombardo, Nadia Aspromonte

  • Open Access

    Evaluation of the Effects of the Sodium–Glucose Cotransporter 2 Inhibitors and Sacubitril/Valsartan Combined Therapy in Patients with HFrEF: An Echocardiographic Study

    by Isabella Fumarulo, Annalisa Pasquini, Giulia La Vecchia, Bianca Pellizzeri, Andriy Sten, Barbara Garramone, Marcello Vaccarella, Salvatore Emanuele Ravenna, Antonella Lombardo, Francesco Burzotta, et al.

    Sodium–glucose cotransporter 2 inhibitors (iSGLT2) have become the fourth pillar of the medical treatment for heart failure with reduced ejection fraction (HFrEF). However, the mechanisms of action of iSGLT2 remain poorly understood. The effectiveness of combined ARNI and iSGLT2 therapy in left ventricular (LV) remodeling is still under study. We aim to investigate the effects of ARNI + iSGLT2 combination therapy in patients affected by HFrEF in terms of ventricular remodeling using speckle tracking echocardiography (STE). In this observational study, 136 patients with HFrEF taking ARNI were enrolled. All patients were evaluated at baseline (before iSGLT2), at 3 months and at 12 months from the beginning of iSGLT2 therapy. Echocardiographic parameters, including STE analysis and volumetric and LV contractile function indices, were collected at the three timepoints. The objectives were (1) to evaluate the effects of ARNI + iSGLT2 combination therapy on ultrasound (US) measurements; (2) to evaluate the effects on the variation of laboratory data indicative of HF (NT-pro-BNP); and (3) to evaluate the medium-long term impact of the ARNI + iSGLT2 combination therapy in terms of major cardiovascular events (MACVE). After only three months of combined ARNI + iSGLT2 therapy, we reported a significant improvement in ventricular and atrial volumetric indices, systolic function indices and myocardial deformation parameters assessed by STE. We also reported a significant decrease in NTproBNP levels. This trend was confirmed at 12 months follow-up. Furthermore, narrowing down the analysis to patients who were already treated with ARNI when they started taking iSGLT2, we reported similar results in the improvement of US parameters and NTproBNP levels. Our study has shown that the ARNI + iSGLT2 combination therapy leads to a clinical improvement and positive ventricular remodeling. Even the single introduction of additional iSGLT-2 in HFrEF patients on an otherwise optimized therapy resulted in a significant improvement in US and laboratory variables. The results of our study suggest implementing iSGLT-2 therapy as soon as possible, as the structural and functional cardiac improvements achieved by these drugs are achieved in the short term and maintained in the long term.


  • Open Access

    Evolution of Cardiac Damage Staged With Echocardiography in Fabry Disease

    by Rosa Lillo, Maria Chiara Meucci, Annamaria Del Franco, Emanuele Monda, Giulia Iannaccone, Raffaello Ditaranto, Federico Di Nicola, Serena Serratore, Antonella Lombardo, Letizia Spinelli, et al.

    Background: Fabry disease can be classified in 4 stages based on the extent of cardiac damage assessed with echocardiography. This staging is strongly associated with prognosis, with a doubled risk increase of cardiovascular events for each stage progression. The aims of the present study were to investigate the evolution of cardiac damage using this staging system during midterm follow‐up and to identify predictors of stage worsening. Methods AND RESULTS: This is a retrospective, multicenter study, which included 168 patients with Fabry disease (38% men) categorized at baseline and follow‐up in 4 stages, defined as follows: stage 0, no cardiac involvement; stage 1, left ventricular hypertrophy; stage 2, left atrial enlargement; and stage 3, ventricular impairment. After a median of 5 years, cardiac stage worsened of at least 1 class in 34 patients (24% of 143 patients in stage 0–2 at baseline), improved in 9 (12% of 73 patients in stages 1–3 at baseline), and remained stable in 125 (74% of the 168 patients enrolled). At multivariable logistic regression analysis, age (odds ratio, 1.05 [95% CI, 1.01–1.09]; P =0.006), male sex (odds ratio, 4.26 [95% CI, 1.54–11.79]; P =0.005), classic phenotype (odds ratio, 4.95 [95% CI, 1.30–18.72]; P =0.018), and renal failure (odds ratio, 10.40 [95% CI, 1.57–68.77]; P =0.015) emerged as independent predictors of cardiac damage stage deterioration. Conclusions: Fabry disease is associated with a high rate of progression of cardiac damage during midterm follow‐up, with ≈24% of patients experiencing cardiac stage worsening. Age, male sex, classic phenotype, and renal failure are independent predictors of stage progression.


  • Open Access

    Transthoracic Echocardiography in Assessing Patients with Suspected Infective Endocarditis (TEASE): An Exploratory Study

    by Nello Cambise, Saverio Tremamunno, Angelo Giuseppe Marino, Ludovica Lenci, Fabio De Benedetto, Antonietta Belmusto, Lorenzo Tinti, Antonio Di Renzo, Federico Di Perna, Giacomo Buonamassa, et al.

    Background: An extensive use of transesophageal echocardiography (TEE) has recently been suggested for the diagnosis of infective endocarditis (IE). In this study, we investigated whether among patients with negative transthoracic echocardiography (TTE), subgroups can be identified among whom TEE can be avoided/delayed. Methods: We conducted a retrospective study of 637 consecutive patients who underwent TEE for suspected IE. We selected 375 patients with negative TTE. For each patient, we obtained age, sex, blood culture (BC), blood exams, evidence of embolism, presence of moderate/severe heart valve disease, valve prostheses, and intracardiac devices. Results: IE was eventually diagnosed in 56 patients. Variables independently associated with IE at multivariate analysis included positive BC (OR 3.45; p = 0.006), evidence of embolism (OR 13.0; p < 0.001), bioprosthetic heart valves (OR 4.31; p < 0.001) and platelet count < 150,000/mL (OR 2.47; p = 0.014). In patients without any of these predictors for IE (n = 81), only 1 had a diagnosis of IE and no in-hospital IE-related deaths occurred. Among patients with negative BC (n = 127), IE prevalence increased with the number of other predictors, but IE-related mortality was 0%. IE prevalence (10.8%) and IE related in-hospital mortality (2.7%) were also rather low in patients with a positive blood culture without any other independent predictors for IE but were 20% (IE-related mortality 3.8%) and 71% (IE-related mortality 28.6%) in those with only one or 2–3 other IE predictors, respectively. Conclusions: Our data suggest that, among patients with suspected IE and negative TTE, subgroups can be identified in whom TEE might be safely avoided or delayed.